Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Patent
1998-06-03
2000-06-06
Weber, Jon P.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
574165, A61K 3448, A01N 3736
Patent
active
060715146
ABSTRACT:
The present invention provides a method of treatment for patients with a variety of thrombotic disorders including, but not limited to, stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. Said treatment is a combination therapy with human aPC and antiplatelet agents including, but not limited to, aspirin (ASA), clopidogrel, ReoPro.RTM. (abciximab), dipyridamole, ticlopidine and IIb/IIIa receptor antagonists. The synergy will result in the ability to reduce the dosages of the agents used in the combination therapy.
REFERENCES:
patent: 4775624 (1988-10-01), Bang et al.
patent: 4981952 (1991-01-01), Yan
patent: 4992373 (1991-02-01), Bang et al.
patent: 5350578 (1994-09-01), Griffin et al.
patent: 5453373 (1995-09-01), Gerlitz et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5618843 (1997-04-01), Fisher et al.
Popma et al., Adjuncts to Thrombolysis for Myocardial Reperfusion, Ann. Intern. Med., vol. 115, No. 1, pp. 34-44, Jul. 1991.
Gruber et al., Generation of Both Plasmin and Activated Protein C During Thrombolytic Therapy with Streptokinase. Blood, vol. 82, No. 10, Suppl. 1, p. 212a, Abstract No. 835, Nov. 1993.
Esmon, C. T., The Regulation of Natural Anticoagulant Pathways, Science, vol. 235, pp. 1348-1352, Mar. 1987.
Eisenberg, P.R., Role of New Anticoagulants as Adjunctive Therapy During Thrombolysis, Am. J. Cardiaol., vol. 67., No. 3, pp. A19-A24, Jan. 1991.
Verstraete, M., Advances in Thromolytic Therapy, Cardiovasc. Drugs Ther., vol. 6, No. 2, pp. 111-124, 1992.
Angelli, G., New Strategies for Enhancing the Speed and Rate of Coronary Reperfusion, Am. J. Cardiol., vol. 72, No. 9, pp. 51G-58G, Dec. 1993.
Runge et al., Inhibition of Platelets and Thrombin: Implications for Treatment of Coronary Artery Thrombosis, Z. Kardiol., vol. 82, Suppl. 2, pp. 83-88, 1993.
Grinnell, et al., "Trans-Activated Expression Of Fully Gamma-Carboxylated Recombinant Human Protein C, An Antithrombotic Factor", Bio/Technology, 5:1189-1192, Nov. 1987.
Remington, The Science and Practice of Pharmacy, Nineteenth Edition, vol. II, pp. 924-925, Mack Publishing Co. (1995).
Yasuda, et al., "Comparative Effects of Aspirin, a Synthetic Thrombin Inhibitor and a Monoclonal Antiplatelet Glycoprotein IIb/IIIa Antibody on Coronary Artery Reperfusion, Reocclusion and Bleeding With Recombinant Tissue-Type Plasminogen Activator in a Canine Perparation", JACC, vol. 16 No. 3, 714-722, Sep. 1990.
Clarke et al., "Combined Administration of Aspirin and a Specific Thrombin Inhibitor in Man", Circulation/Clinical Investigation, vol. 83, 1510-1518, 1991.
Jang et al., "Antiplatelets", Current Science/ Coronary Artery Disease, vol. 3, No. 11, 1030-1036, Nov. 1992.
Zoldhelyi, et al., "Antithrombins as conjuctive therapy in arterial thrombolysis", Current Science/Coronary Artery Disease, vol. 3, No. 11, 1003-1009, Nov. 1992.
Heiden, et al., "Impairment by Heparin of Primary Haemostasis and Platelet [.sup.14 C]5-Hydroxytryptamine Release", British Journal of Haematology, 36:427-436, 1977.
Grinnell Brian William
Jakubowski Joseph Anthony
Apelgren Lynn D.
Barrett Brian P.
Caltrider Steven P.
Eli Lilly and Company
Weber Jon P.
LandOfFree
Methods for treating thrombotic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating thrombotic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating thrombotic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2211183